Sera Prognostics Inc. (SERA)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Sera Prognostics Q2 Earnings Call Highlights
Sera Prognostics NASDAQ: SERA reported modest second-quarter revenue while outlining progress in payer engagement, Illinois Medicaid policy, clinical evidence and European regulatory preparations for its PreTRM Test-guided care platform.
Sera Prognostics, Inc. (SERA) Q2 2026 Earnings Call Transcript
Sera Prognostics, Inc. (SERA) Q2 2026 Earnings Call Transcript
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Misses Revenue Estimates
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.16 per share a year ago.
Sera Prognostics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 John H. Burbank III Passport Capital LLC | 5.5M | $29.47M | $10.78M | -$18.7M | -63.44% |
 Kimberly Van Winkle Twelve Points Wealth Management LLC | 43,388 | $256,856.96 | $89,813.16 | -$167,043.8 | -65.03% |
 Rekah Franca Catalyst Funds Management Pty Ltd. | 38,890 | $75,728.4 | $80,502.3 | $4,773.9 | 6.3% |
 Joseph Gentili Riverview Capital Advisers LLC | 12,669 | $35,093.72 | $25,591.38 | -$9,502.34 | -27.08% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 4 | $8 | $8 | - | - |
Sera Prognostics Inc. (SERA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Sera Prognostics Inc. ever had a stock split?
Sera Prognostics Inc. Profile
| Professional Services Industry | Industrials Sector | Zhenya Lindgardt CEO | NASDAQ (NMS) Exchange | 81749D107 CUSIP |
| US Country | 72 Employees | - Last Dividend | - Last Split | 15 Jul 2021 IPO Date |
Overview
Sera Prognostics, Inc. is a pioneering entity in the domain of women’s health diagnostics, with its operational base in the United States. Since its inception in 2008, the company has been at the forefront of discovering, developing, and bringing to market biomarker tests designed to ameliorate pregnancy outcomes. With a strategic focus on enhancing the health of women during pregnancy, Sera Prognostics is committed to leveraging cutting-edge scientific research to create diagnostic solutions that cater to a range of pregnancy-related conditions. Its headquarters are located in Salt Lake City, Utah, reflecting its deep roots and commitment to innovation within the biomedical industry.
Products and Services
- PreTRM Test: The flagship product of Sera Prognostics is the PreTRM test, a revolutionary blood-based biomarker test aimed at assessing the risk of spontaneous preterm birth in singleton pregnancies. This test exemplifies the company's dedication to preventing preterm births through early detection and intervention strategies.
- Preeclampsia Test: Sera Prognostics is in the process of developing a dedicated test for the early detection of preeclampsia, a condition that can have severe implications for both mother and child. Early detection is crucial for managing and mitigating the risks associated with this condition.
- Molecular Time-to-Birth: This upcoming product is designed to predict the molecular time-to-birth accurately, providing expectant parents and healthcare providers with valuable insights into the expected delivery timeframe.
- Predictive Analytics: Leveraging advanced analytics, Sera Prognostics aims to offer predictive insights into various pregnancy-related conditions, enabling proactive management and interventions.
- Gestational Diabetes Mellitus: The company is also developing diagnostic tests for early detection of gestational diabetes mellitus, facilitating timely interventions to ensure maternal and fetal health.
- Fetal Growth Restriction: Sera Prognostics is working on tools for the early detection of fetal growth restriction, a condition that can lead to significant health issues for the child if not addressed promptly.
- Stillbirth: Recognizing the profound impact of stillbirth, the company is developing diagnostics to identify high-risk pregnancies, aiming to reduce the incidence of this tragic outcome.
- Postpartum Depression: With an understanding of the importance of mental health during the postpartum period, Sera Prognostics is exploring solutions for the early detection and management of postpartum depression.
